De Young BR - Search Results

1

C-erb B2 (Her2/neu) is neither overexpressed nor amplified in hepatic neoplasms.

Vlasoff DM, Baschinsky DY, De Young BR, Morrison CD, Nuovo GJ, Frankel WL. Vlasoff DM, et al. Among authors: de young br. Appl Immunohistochem Mol Morphol. 2002 Sep;10(3):237-41. doi: 10.1097/00129039-200209000-00009. Appl Immunohistochem Mol Morphol. 2002. PMID: 12373150

2

Immunohistochemical analysis of biliary tract lesions.

Tan G, Yilmaz A, De Young BR, Behling C, Lehman A, Frankel WL. Tan G, et al. Among authors: de young br. Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):193-7. doi: 10.1097/00129039-200409000-00002. Appl Immunohistochem Mol Morphol. 2004. PMID: 15551730

3

Immunohistochemical analysis of hepatocellular and adenocarcinoma in the liver: MOC31 compares favorably with other putative markers.

Porcell AI, De Young BR, Proca DM, Frankel WL. Porcell AI, et al. Among authors: de young br. Mod Pathol. 2000 Jul;13(7):773-8. doi: 10.1038/modpathol.3880134. Mod Pathol. 2000. PMID: 10912937

4

Primary localized extranodal hodgkin disease of the transverse colon.

Vadmal MS, LaValle GP, DeYoung BR, Frankel WL, Marsh WL. Vadmal MS, et al. Arch Pathol Lab Med. 2000 Dec;124(12):1824-7. doi: 10.5858/2000-124-1824-PLEHDO. Arch Pathol Lab Med. 2000. PMID: 11100066 Free article.

5

MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report of findings and review of other utilized markers.

Proca DM, Niemann TH, Porcell AI, DeYoung BR. Proca DM, et al. Appl Immunohistochem Mol Morphol. 2000 Jun;8(2):120-5. doi: 10.1097/00129039-200006000-00006. Appl Immunohistochem Mol Morphol. 2000. PMID: 10937059 Review.

6

Her-2/neu expression in salivary duct carcinoma: an immunohistochemical and chromogenic in situ hybridization study.

Johnson CJ, Barry MB, Vasef MA, Deyoung BR. Johnson CJ, et al. Appl Immunohistochem Mol Morphol. 2008 Jan;16(1):54-8. doi: 10.1097/PAI.0b013e31802e91b2. Appl Immunohistochem Mol Morphol. 2008. PMID: 18091319

7

CD31 immunoreactivity in small round cell tumors.

Nicholson SA, McDermott MB, DeYoung BR, Swanson PE. Nicholson SA, et al. Appl Immunohistochem Mol Morphol. 2000 Mar;8(1):19-24. doi: 10.1097/00129039-200003000-00003. Appl Immunohistochem Mol Morphol. 2000. PMID: 10937044

8

MOC-31 aids in the differentiation of metastatic adenocarcinoma from hepatocellular carcinoma.

Niemann TH, Hughes JH, De Young BR. Niemann TH, et al. Among authors: de young br. Cancer. 1999 Oct 25;87(5):295-8. Cancer. 1999. PMID: 10536355

9

Anti-MOC-31: a potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panel.

Sosolik RC, McGaughy VR, De Young BR. Sosolik RC, et al. Among authors: de young br. Mod Pathol. 1997 Jul;10(7):716-9. Mod Pathol. 1997. PMID: 9237183

10

CD31 immunoreactivity in carcinomas and mesotheliomas.

De Young BR, Frierson HF Jr, Ly MN, Smith D, Swanson PE. De Young BR, et al. Am J Clin Pathol. 1998 Sep;110(3):374-7. doi: 10.1093/ajcp/110.3.374. Am J Clin Pathol. 1998. PMID: 9728613

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

88 results

Search Page

Filters